Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/92269
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaek, Jong-Suepen
dc.contributor.authorTee, Jie Kaien
dc.contributor.authorPang, Yi Yunen
dc.contributor.authorTan, Ern Yuen
dc.contributor.authorLim, Kah Leongen
dc.contributor.authorHo, Han Kiaten
dc.contributor.authorLoo, Joachim Say Chyeen
dc.date.accessioned2019-07-25T08:47:50Zen
dc.date.accessioned2019-12-06T18:20:21Z-
dc.date.available2019-07-25T08:47:50Zen
dc.date.available2019-12-06T18:20:21Z-
dc.date.issued2018en
dc.identifier.citationBaek, J.-S., Tee, J. K., Pang, Y. Y., Tan, E. Y., Lim, K. L., Ho, H. K., & Loo, J. S. C. (2018). Improved bioavailability of levodopa using floatable spray-coated microcapsules for the management of Parkinson’s disease. NeuroMolecular Medicine, 20(2), 262-270. doi:10.1007/s12017-018-8491-0en
dc.identifier.issn1535-1084en
dc.identifier.urihttps://hdl.handle.net/10356/92269-
dc.identifier.urihttp://hdl.handle.net/10220/49468en
dc.description.abstractOral administration of levodopa (LD) is the gold standard in managing Parkinson’s disease (PD). Although LD is the most effective drug in treating PD, chronic administration of LD induces levodopa-induced dyskinesia. A continuous and sustained provision of LD to the brain could, therefore, reduce peak-dose dyskinesia. In commercial oral formulations, LD is co-administrated with an AADC inhibitor (carbidopa) and a COMT inhibitor (entacapone) to enhance its bioavailability. Nevertheless, patients are known to take up to five tablets a day because of poor sustained-releasing capabilities that lead to fluctuations in plasma concentrations. To achieve a prolonged release of LD with the aim of improving its bioavailability, floatable spray-coated microcapsules containing all three PD drugs were developed. This gastro-retentive delivery system showed sustained release of all PD drugs, at similar release kinetics. Pharmacokinetics study was conducted and this newly developed formulation showed a more plateaued delivery of LD that is void of the plasma concentration fluctuations observed for the control (commercial formulation). At the same time, measurements of LD and dopamine of mice administered with this formulation showed enhanced bioavailability of LD. This study highlights a floatable, sustained-releasing delivery system in achieving improved pharmacokinetics data compared to a commercial formulation.en
dc.description.sponsorshipMOE (Min. of Education, S’pore)en
dc.format.extent23 p.en
dc.language.isoenen
dc.relation.ispartofseriesNeuroMolecular Medicineen
dc.rights© 2018 Springer Science+Business Media US. All rights reserved.This is a post-peer-review, pre-copyedit version of an article published in NeuroMolecular Medicine. The final authenticated version is available online at: http://dx.doi.org/10.1007/s12017-018-8491-0en
dc.subjectControlled Releaseen
dc.subjectDRNTU::Engineering::Materialsen
dc.subjectLevodopa-induced Dyskinesiaen
dc.titleImproved bioavailability of levodopa using floatable spray-coated microcapsules for the management of Parkinson’s diseaseen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Materials Science and Engineeringen
dc.contributor.researchSingapore Centre for Environmental Life Sciences and Engineeringen
dc.identifier.doihttp://dx.doi.org/10.1007/s12017-018-8491-0en
dc.description.versionAccepted versionen
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:MSE Journal Articles

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.